Furthermore, CRISPR/Cas9-mediated double PDHA1/OGDH knock-down significantly reduced CD8+ T cell intra-tumoral motility as assessed using tumor slice derived from the BXPC3-NSG model (Fig. 1M and Supplementary Movie 13). This evidence concerns the gene CD8A and neoplasm.